Marshall Financial Group LLC Increases Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Marshall Financial Group LLC lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,719 shares of the company’s stock after purchasing an additional 154 shares during the period. Marshall Financial Group LLC’s holdings in IDEXX Laboratories were worth $928,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Valley National Advisers Inc. lifted its position in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after purchasing an additional 22 shares during the period. Riverview Trust Co bought a new stake in IDEXX Laboratories during the 1st quarter valued at about $26,000. Geo Capital Gestora de Recursos Ltd bought a new stake in IDEXX Laboratories during the 3rd quarter valued at about $28,000. DSM Capital Partners LLC bought a new stake in IDEXX Laboratories during the 4th quarter valued at about $33,000. Finally, Venturi Wealth Management LLC increased its stake in IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after purchasing an additional 43 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.18% of the company’s stock.

Analyst Ratings Changes

IDXX has been the subject of a number of research analyst reports. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Barclays reduced their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $477.49 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39. The company has a market capitalization of $39.44 billion, a P/E ratio of 46.22, a P/E/G ratio of 3.90 and a beta of 1.32. The firm’s 50 day simple moving average is $500.62 and its two-hundred day simple moving average is $524.93.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The business had revenue of $964.10 million for the quarter, compared to the consensus estimate of $965.43 million. Research analysts expect that IDEXX Laboratories, Inc. will post 11.03 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.